Home » Stocks » NTRA

Natera, Inc. (NTRA)

Stock Price: $90.76 USD -0.43 (-0.47%)
Updated December 2, 4:00 PM EST - Market closed
After-hours: $90.04 -0.72 (-0.79%) Dec 2, 6:43 PM

Stock Price Chart

Key Info

Market Cap 7.75B
Revenue (ttm) 361.87M
Net Income (ttm) -188.52M
Shares Out 80.91M
EPS (ttm) -2.39
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day December 2
Last Price $90.76
Previous Close $91.19
Change ($) -0.43
Change (%) -0.47%
Day's Open 90.34
Day's Range 88.99 - 91.36
Day's Volume 523,992
52-Week Range 17.27 - 91.36

More Stats

Market Cap 7.75B
Enterprise Value 7.21B
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 80.91M
Float n/a
EPS (basic) -2.38
EPS (diluted) -2.39
FCF / Share -1.72
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 4.85M
Short Ratio 9.02
Short % of Float n/a
Beta 1.50
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 21.41
PB Ratio 13.47
Revenue 361.87M
Operating Income -177.12M
Net Income -188.52M
Free Cash Flow -138.75M
Net Cash 538.28M
Net Cash / Share 6.31
Gross Margin 35.06%
Operating Margin -48.95%
Profit Margin -52.10%
FCF Margin -38.34%
ROA -16.31%
ROE -60.74%
ROIC -27.70%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (9)

Buy 8
Overweight 1
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$89.89*
(-0.96% downside)
Low
80.0
Current: $90.76
High
95.0
Target: 89.89
*Average 12-month price target from 9 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013
Revenue30225821021319015955.17
Revenue Growth17.34%22.91%-1.36%11.64%19.5%188.72%-
Gross Profit12791.6070.0376.9477.5180.8917.90
Operating Income-116-115-135-101-59.840.67-25.27
Net Income-125-128-138-100-70.28-5.15-37.11
Shares Outstanding69.5657.8553.3151.5826.204.803.84
Earnings Per Share-1.79-2.22-2.59-1.95-2.68-1.07-9.66
Operating Cash Flow-63.44-70.58-97.83-74.05-37.8310.49-24.13
Capital Expenditures-4.97-3.88-9.87-23.14-7.39-9.94-8.25
Free Cash Flow-68.41-74.46-108-97.19-45.220.55-32.38
Cash & Equivalents44115411914623187.1831.39
Total Debt15012412349.6242.0926.8124.31
Net Cash / Debt29130.36-4.3196.4918860.367.09
Assets58326821521126512459.72
Liabilities30423618910480.4854.3546.03
Book Value27932.1625.42106185-171-172
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Natera, Inc.
Employees 1,039

Stock Information

Ticker Symbol NTRA
Stock Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Unique Identifier NASDAQ: NTRA
IPO Date July 2, 2015

Description

Natera, Inc. provides preconception and prenatal genetic testing services. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora products of conception test to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by analyzing the fragments of fetal deoxyribonucleic acid in a pregnant mother's blood and a blood sample from the alleged father. In addition, it offers Constellation, a cloud-based software product that allows laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests; and Signatera, a circulating tumor DNA technology that analyzes and tracks mutations to an individual's tumor. The company offers products through its direct sales force, as well as through a network of approximately 100 laboratory and distribution partners in the United States and internationally. It has a partnership agreement with BGI Genomics Company to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is headquartered in San Carlos, California.